Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more
Open Access

Facilitation of transmitter release from rat sympathetic neurons via presynaptic P2Y1 receptors

BMC Pharmacology20088(Suppl 1):A8

https://doi.org/10.1186/1471-2210-8-S1-A8

Published: 5 November 2008

P2Y1 receptor antagonists are being developed as antithrombotics. In the vasculature, P2Y1 receptors are not only expressed in platelets, but also in the endothelium where they indirectly mediate vasorelaxation. By blockade of these latter effects, P2Y1 antagonists may cause untoward effects. Here, we investigated whether vascular sympathetic axon terminals also possess P2Y1 receptors by determining [3H]noradrenaline release from superior cervical ganglion neurons in cell culture. ADP inhibited electrically evoked release, but this effect was reverted into facilitation when either P2Y12 receptors were blocked by cangrelor or their signalling cascade was interrupted by pertussis toxin. The facilitation by ADP was also observed with K+ stimulation in the presence of tetrodotoxin, was mimicked by 2-methlythio-ATP, and was prevented by suramin, reactive blue 2, and MRS2179. The facilitation by ADP was abolished by the phospholipase C inhibitor U73122, but was not affected by cholera toxin to down-regulate Gs proteins, by H-7 to block protein kinases, or by thapsigargin to deplete intracellular Ca2+ stores. In patch clamp recordings, activation of P2Y1 receptors led to an inhibition of KCNQ channels, but the KCNQ channel modulators retigabine and XE 991 did not alter electrically evoked noradrenaline release or its facilitation by ADP. These results show that presynaptic P2Y1 receptors mediate facilitation of transmitter release from sympathetic nerve terminals via phospholipase C, and interference with this mechanism by P2Y1 antagonists can be expected to counteract the previously described vasoconstrictive action of these drugs.

Declarations

Acknowledgements

Supported by the Austrian Science Fund FWF (P17611 and W1205).

Authors’ Affiliations

(1)
Institute of Pharmacology, Center for Biomolecular Medicine and Pharmacology, Medical University of Vienna

Copyright

© Chandaka et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd.

Advertisement